Cargando…
Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of multi-drug resistant tuberculosis in decades. In vitro resistance to BDQ was previously shown to be due to target-based mutations. Here we report that non-target based resistance to BDQ, and cross-resista...
Autores principales: | Andries, Koen, Villellas, Cristina, Coeck, Nele, Thys, Kim, Gevers, Tom, Vranckx, Luc, Lounis, Nacer, de Jong, Bouke C., Koul, Anil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092087/ https://www.ncbi.nlm.nih.gov/pubmed/25010492 http://dx.doi.org/10.1371/journal.pone.0102135 |
Ejemplares similares
-
Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline
por: Villellas, Cristina, et al.
Publicado: (2017) -
Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678
por: Snobre, J., et al.
Publicado: (2023) -
Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism
por: Koul, Anil, et al.
Publicado: (2014) -
Targeting Energy Metabolism in Mycobacterium tuberculosis, a New Paradigm in Antimycobacterial Drug Discovery
por: Bald, Dirk, et al.
Publicado: (2017) -
Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis
por: Coeck, Nele, et al.
Publicado: (2016)